Ustekinumab - Global and China Top Players Market Share and Ranking 2025- YH Research

日本语 | 中文

Home > Reports >Pharma & Healthcare > Ustekinumab - Global and China Top Players Market Share and Ranking 2025

Ustekinumab - Global and China Top Players Market Share and Ranking 2025

Publication Date: 2025-08-19
Report Id: 2222460
Industry: Pharma & Healthcare
Report Page: 115
Chart: 113

PDF Download

Publication Date: 2025-08-19
Report Id: 2222460
Industry: Pharma & Healthcare
Report Page: 115
Chart: 113

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Ustekinumab Definition
1.2 Global Ustekinumab Market Size and Forecast
1.2.1 By Consumption Value, Global Ustekinumab Market Size, 2020-2031
1.2.2 By Sales Quantity, Global Ustekinumab Market Size, 2020-2031
1.2.3 Global Ustekinumab Average Selling Price (ASP), 2020-2031
1.3 China Ustekinumab Market Size and Forecast
1.3.1 By Consumption Value, China Ustekinumab Market Size, 2020-2031
1.3.2 By Sales Quantity, China Ustekinumab Market Size, 2020-2031
1.3.3 China Ustekinumab Average Selling Price (ASP), 2020-2031
1.4 Share of China Ustekinumab Market with Respect to the Global Market
1.4.1 By Consumption Value, China Ustekinumab Market Share in Global, 2020-2031
1.4.2 By Sales Quantity, China Ustekinumab Market Share in Global, 2020-2031
1.4.3 Ustekinumab Market Size: China VS Global, 2020-2031
1.5 Ustekinumab Market Dynamics
1.5.1 Ustekinumab Market Drivers
1.5.2 Ustekinumab Market Restraints
1.5.3 Ustekinumab Industry Trends
1.5.4 Ustekinumab Industry Policy

2 Global Leading Manufacturers and Market Share
2.1 By Revenue of Ustekinumab, Global Market Share by Company, 2020-2025
2.2 By Sales Quantity of Ustekinumab, Global Market Share by Company, 2020-2025
2.3 Ustekinumab Average Selling Price (ASP) by Company, 2020-2025
2.4 Global Ustekinumab Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.5 Global Ustekinumab Concentration Ratio
2.6 Global Ustekinumab Mergers & Acquisitions, Expansion Plans
2.7 Global Ustekinumab Manufacturers Product Type
2.8 Head Office and Ustekinumab Production Site of Key Manufacturer
2.9 Ustekinumab Capacity of Major Manufacturers and Future Plan

3 China Leading Manufacturers and Market Share
3.1 By Revenue of Ustekinumab, China Market Share by Company, 2020-2025
3.2 By Sales Quantity of Ustekinumab, China Market Share by Company, 2020-2025
3.3 China Ustekinumab Ustekinumab Participants, Market Position (Tier 1, Tier 2, and Tier 3)

4 Global Producing Regions
4.1 Global Ustekinumab Capacity, Output and Capacity Utilization, 2020-2031
4.2 Global Ustekinumab Capacity by Region
4.3 Global Ustekinumab Production & Forecast by Region, 2020 VS 2024 VS 2031
4.4 Global Ustekinumab Production by Region, 2020-2031
4.5 Global Ustekinumab Production Market Share & Forecast by Region, 2020-2031

5 Industry Chain Analysis
5.1 Ustekinumab Industry Chain
5.2 Ustekinumab Upstream Analysis
5.2.1 Ustekinumab Core Raw Materials
5.2.2 Main Manufacturers of Ustekinumab Core Raw Materials
5.3 Midstream Analysis
5.4 Downstream Analysis
5.5 Ustekinumab Production Mode
5.6 Ustekinumab Procurement Model
5.7 Ustekinumab Industry Sales Model and Sales Channels
5.7.1 Ustekinumab Sales Model
5.7.2 Ustekinumab Typical Distributors

6 Sights by Type
6.1 Ustekinumab Classification
6.1.1 Intravenous
6.1.2 Subcutaneous
6.2 by Type, Global Ustekinumab Consumption Value & CAGR, 2020 VS 2024 VS 2031
6.3 by Type, Global Ustekinumab Consumption Value, 2020-2031
6.4 by Type, Global Ustekinumab Sales Quantity, 2020-2031
6.5 by Type, Global Ustekinumab Average Selling Price (ASP), 2020-2031

7 Sights by Application
7.1 Ustekinumab Segment by Application
7.1.1 Plaque Psoriasis
7.1.2 Psoriatic Arthritis
7.1.3 Crohn’s Disease
7.1.4 Ulcerative Colitis
7.1.5 Others
7.2 by Application, Global Ustekinumab Consumption Value & CAGR, 2020 VS 2024 VS 2031
7.3 by Application, Global Ustekinumab Consumption Value, 2020-2031
7.4 by Application, Global Ustekinumab Sales Quantity, 2020-2031
7.5 by Application, Global Ustekinumab Price, 2020-2031

8 Sales Sights by Region
8.1 By Region, Global Ustekinumab Consumption Value, 2020 VS 2024 VS 2031
8.2 By Region, Global Ustekinumab Consumption Value, 2020-2031
8.3 By Region, Global Ustekinumab Sales Quantity, 2020-2031
8.4 North America
8.4.1 North America Ustekinumab Market Size & Forecasts, 2020-2031
8.4.2 By Country, North America Ustekinumab Market Size Market Share
8.5 Europe
8.5.1 Europe Ustekinumab Market Size & Forecasts, 2020-2031
8.5.2 By Country, Europe Ustekinumab Market Size Market Share
8.6 Asia Pacific
8.6.1 Asia Pacific Ustekinumab Market Size & Forecasts, 2020-2031
8.6.2 By Country/Region, Asia Pacific Ustekinumab Market Size Market Share
8.7 South America
8.7.1 South America Ustekinumab Market Size & Forecasts, 2020-2031
8.7.2 By Country, South America Ustekinumab Market Size Market Share
8.8 Middle East & Africa

9 Sales Sights by Country Level
9.1 By Country, Global Ustekinumab Market Size & CAGR, 2020 VS 2024 VS 2031
9.2 By Country, Global Ustekinumab Consumption Value, 2020-2031
9.3 By Country, Global Ustekinumab Sales Quantity, 2020-2031
9.4 United States
9.4.1 United States Ustekinumab Market Size, 2020-2031
9.4.2 by Type, United States Ustekinumab Sales Quantity Market Share, 2024 VS 2031
9.4.3 by Application, United States Ustekinumab Sales Quantity Market Share, 2024 VS 2031
9.5 Europe
9.5.1 Europe Ustekinumab Market Size, 2020-2031
9.5.2 by Type, Europe Ustekinumab Sales Quantity Market Share, 2024 VS 2031
9.5.3 by Application, Europe Ustekinumab Sales Quantity Market Share, 2024 VS 2031
9.6 China
9.6.1 China Ustekinumab Market Size, 2020-2031
9.6.2 by Type, China Ustekinumab Sales Quantity Market Share, 2024 VS 2031
9.6.3 by Application, China Ustekinumab Sales Quantity Market Share, 2024 VS 2031
9.7 Japan
9.7.1 Japan Ustekinumab Market Size, 2020-2031
9.7.2 by Type, Japan Ustekinumab Sales Quantity Market Share, 2024 VS 2031
9.7.3 by Application, Japan Ustekinumab Sales Quantity Market Share, 2024 VS 2031
9.8 South Korea
9.8.1 South Korea Ustekinumab Market Size, 2020-2031
9.8.2 by Type, South Korea Ustekinumab Sales Quantity Market Share, 2024 VS 2031
9.8.3 by Application, South Korea Ustekinumab Sales Quantity Market Share, 2024 VS 2031
9.9 Southeast Asia
9.9.1 Southeast Asia Ustekinumab Market Size, 2020-2031
9.9.2 by Type, Southeast Asia Ustekinumab Sales Quantity Market Share, 2024 VS 2031
9.9.3 by Application, Southeast Asia Ustekinumab Sales Quantity Market Share, 2024 VS 2031
9.10 India
9.10.1 India Ustekinumab Market Size, 2020-2031
9.10.2 by Type, India Ustekinumab Sales Quantity Market Share, 2024 VS 2031
9.10.3 by Application, India Ustekinumab Sales Quantity Market Share, 2024 VS 2031
9.11 Middle East & Africa
9.11.1 Middle East & Africa Ustekinumab Market Size, 2020-2031
9.11.2 by Type, Middle East & Africa Ustekinumab Sales Quantity Market Share, 2024 VS 2031
9.11.3 by Application, Middle East & Africa Ustekinumab Sales Quantity Market Share, 2024 VS 2031

10 Manufacturers Profile
10.1 Meiji
10.1.1 Meiji Company Information, Head Office, Market Area, and Industry Position
10.1.2 Meiji Ustekinumab Models, Specifications, and Application
10.1.3 Meiji Ustekinumab Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
10.1.4 Meiji Company Profile and Main Business
10.1.5 Meiji Recent Developments
10.2 Johnson & Johnson
10.2.1 Johnson & Johnson Company Information, Head Office, Market Area, and Industry Position
10.2.2 Johnson & Johnson Ustekinumab Models, Specifications, and Application
10.2.3 Johnson & Johnson Ustekinumab Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
10.2.4 Johnson & Johnson Company Profile and Main Business
10.2.5 Johnson & Johnson Recent Developments
10.3 Alvotech
10.3.1 Alvotech Company Information, Head Office, Market Area, and Industry Position
10.3.2 Alvotech Ustekinumab Models, Specifications, and Application
10.3.3 Alvotech Ustekinumab Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
10.3.4 Alvotech Company Profile and Main Business
10.3.5 Alvotech Recent Developments
10.4 Fuji Pharma
10.4.1 Fuji Pharma Company Information, Head Office, Market Area, and Industry Position
10.4.2 Fuji Pharma Ustekinumab Models, Specifications, and Application
10.4.3 Fuji Pharma Ustekinumab Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
10.4.4 Fuji Pharma Company Profile and Main Business
10.4.5 Fuji Pharma Recent Developments
10.5 Mitsubishi Tanabe
10.5.1 Mitsubishi Tanabe Company Information, Head Office, Market Area, and Industry Position
10.5.2 Mitsubishi Tanabe Ustekinumab Models, Specifications, and Application
10.5.3 Mitsubishi Tanabe Ustekinumab Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
10.5.4 Mitsubishi Tanabe Company Profile and Main Business
10.5.5 Mitsubishi Tanabe Recent Developments
10.6 Stada
10.6.1 Stada Company Information, Head Office, Market Area, and Industry Position
10.6.2 Stada Ustekinumab Models, Specifications, and Application
10.6.3 Stada Ustekinumab Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
10.6.4 Stada Company Profile and Main Business
10.6.5 Stada Recent Developments
10.7 EPIRUS BioPharma
10.7.1 EPIRUS BioPharma Company Information, Head Office, Market Area, and Industry Position
10.7.2 EPIRUS BioPharma Ustekinumab Models, Specifications, and Application
10.7.3 EPIRUS BioPharma Ustekinumab Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
10.7.4 EPIRUS BioPharma Company Profile and Main Business
10.7.5 EPIRUS BioPharma Recent Developments
10.8 Formycon
10.8.1 Formycon Company Information, Head Office, Market Area, and Industry Position
10.8.2 Formycon Ustekinumab Models, Specifications, and Application
10.8.3 Formycon Ustekinumab Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
10.8.4 Formycon Company Profile and Main Business
10.8.5 Formycon Recent Developments
10.9 NeuClone
10.9.1 NeuClone Company Information, Head Office, Market Area, and Industry Position
10.9.2 NeuClone Ustekinumab Models, Specifications, and Application
10.9.3 NeuClone Ustekinumab Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
10.9.4 NeuClone Company Profile and Main Business
10.9.5 NeuClone Recent Developments
10.10 Bio-Thera Solutions
10.10.1 Bio-Thera Solutions Company Information, Head Office, Market Area, and Industry Position
10.10.2 Bio-Thera Solutions Ustekinumab Models, Specifications, and Application
10.10.3 Bio-Thera Solutions Ustekinumab Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
10.10.4 Bio-Thera Solutions Company Profile and Main Business
10.10.5 Bio-Thera Solutions Recent Developments
10.11 Huadong Medicine
10.11.1 Huadong Medicine Company Information, Head Office, Market Area, and Industry Position
10.11.2 Huadong Medicine Ustekinumab Models, Specifications, and Application
10.11.3 Huadong Medicine Ustekinumab Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
10.11.4 Huadong Medicine Company Profile and Main Business
10.11.5 Huadong Medicine Recent Developments
10.12 Amgen
10.12.1 Amgen Company Information, Head Office, Market Area, and Industry Position
10.12.2 Amgen Ustekinumab Models, Specifications, and Application
10.12.3 Amgen Ustekinumab Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
10.12.4 Amgen Company Profile and Main Business
10.12.5 Amgen Recent Developments
10.13 Sandoz
10.13.1 Sandoz Company Information, Head Office, Market Area, and Industry Position
10.13.2 Sandoz Ustekinumab Models, Specifications, and Application
10.13.3 Sandoz Ustekinumab Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
10.13.4 Sandoz Company Profile and Main Business
10.13.5 Sandoz Recent Developments
10.14 Biocon Biologics
10.14.1 Biocon Biologics Company Information, Head Office, Market Area, and Industry Position
10.14.2 Biocon Biologics Ustekinumab Models, Specifications, and Application
10.14.3 Biocon Biologics Ustekinumab Sales Quantity, Revenue, Price and Gross Margin, 2020-2025
10.14.4 Biocon Biologics Company Profile and Main Business
10.14.5 Biocon Biologics Recent Developments

11 Conclusion

12 Appendix
12.1 Research Methodology
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Market Estimation Model
12.4 Disclaimer

According to YH Research, the global market for Ustekinumab should grow from US$ million in 2024 to US$ million by 2031, with a CAGR of %for the period of 2025-2031.

The strategic recalibration of 2025 U.S. tariff mechanisms is redefining global economic governance norms. This study deciphers the transmission mechanisms of tariff escalation pathways and global policy responses on corporate investment strategies, regional trade networks, and critical material supply architectures.

Ustekinumab is a fully human IgG1κ monoclonal antibody that specifically binds to the p40 protein subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23), blocking their interaction with cell surface receptors and suppressing related inflammatory responses. It is indicated for the treatment of immune-mediated disorders such as moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. In 2024, the production volume of ustekinumab was 6.12 million syringes, with an average price of USD 3,566 per syringe.

Market Overview
From 2024 to 2025 the ustekinumab landscape has pivoted to multi-biosimilar competition: the EU moved first in January 2024 (Uzpruvo by STADA/Alvotech), Japan approvals were in place since 2023 (Fuji Pharma with Alvotech), China granted its first domestic approval in October 2024 (Huadong Medicine/QX001S), and the U.S. became a crowded arena in 1H25 with several launches (Selarsdi by Teva/Alvotech, Otulfi by Fresenius Kabi/Formycon, Imuldosa by Dong-A ST/Meiji/Accord, and Starjemza by Hikma/Bio-Thera). J&J’s ex-U.S. Stelara sales started to feel intensified pressure as biosimilars expanded geographically.

Regional Structure
Based on approval/launch timing, access dynamics and the originator’s disclosed regional trends, the estimated 1H25 revenue split for ustekinumab (originator + biosimilars) is: United States 62%, Europe 18%, Japan 7%, China 5%, Rest of World 8% (summing to 100%). The EU’s early 2024 launches reduced the originator’s share, the U.S. turned competitive in 2025 with interchangeable products and dual IV/SC formulations, while Japan and China—despite approvals—remain smaller in absolute value versus the U.S. This estimate is anchored to J&J’s regional sales structure and the actual approval/launch cadence.

Key Manufacturers & Competition
Active players include the originator Johnson & Johnson; biosimilar entrants Teva/Alvotech (Selarsdi; interchangeable), STADA/Alvotech (Uzpruvo in the EU), Fresenius Kabi/Formycon (Otulfi; interchangeable; IV and SC), Dong-A ST/Meiji/Accord (Imuldosa; US/EU approvals with UK/IE launches), Hikma/Bio-Thera (Starjemza; US), plus Fuji Pharma (Japan commercialization with Alvotech) and Huadong Medicine (first domestic approval in China). Competition is driven by interchangeability, full-route coverage (SC + IV), industrial scale/release cycle, and access/contracting speed. NeuClone remains earlier-stage; EPIRUS BioPharma has no recent authoritative disclosures tied to this asset.

Technology Trends & Innovation
The focus is on tight analytical/clinical matching plus differentiation via “interchangeability,” full-formulation portfolios (SC and IV), high-concentration prefilled devices/auto-injectors, and robust global CMC/release networks. Otulfi’s interchangeable designation with both IV and SC underscores the advantage of complete modality coverage; Alvotech’s centralized Reykjavik manufacturing combined with regional commercialization partners exemplifies a “central-make, local-sell” operating model.

Policy & Growth Drivers
Clear regulatory pathways and frequent approvals across the U.S./EU/Japan, together with Europe’s procurement-driven uptake and the U.S. patent expiry in 2025, are elevating price competition and substitution rates. China’s first domestic approval in 2024 and subsequent indication filings improve affordability and access. In Japan, coordinated promotion arrangements (e.g., with Mitsubishi Tanabe) remain relevant during the transition.

This report studies and analyses global Ustekinumab status and future trends, helps the client to determine the Ustekinumab market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Ustekinumab, and provides market size (in K Units & US$ million) and Year-over-Year growth, considering 2024 as the base year.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

To assess the competitive environment within the market including supplier revenue, market share, and company profiles.

Highlights
(1) Global Ustekinumab market size, history data 2020-2025, and forecast data 2026-2031, (US$ million) & (K Units)
(2) Global Ustekinumab sales, revenue, price by company, market share and industry ranking 2020-2025, (US$ million) & (K Units)
(3) China Ustekinumab sales, revenue, price by company, market share and industry ranking 2020-2025, (US$ million) & (K Units)
(4) Global Ustekinumab key consuming regions, consumption quantity, consumption value and demand structure
(5) Global Ustekinumab key producing regions, capacity, production, and year over year growth
(6) Ustekinumab industry chains, upstream, midstream and downstream
Market segment by players, this report covers
Meiji
Johnson & Johnson
Alvotech
Fuji Pharma
Mitsubishi Tanabe
Stada
EPIRUS BioPharma
Formycon
NeuClone
Bio-Thera Solutions
Huadong Medicine
Amgen
Sandoz
Biocon Biologics

Market segment by Type, covers
Intravenous
Subcutaneous

Market segment by Application, can be divided into
Plaque Psoriasis
Psoriatic Arthritis
Crohn’s Disease
Ulcerative Colitis
Others

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe Ustekinumab product scope, global sales quantity, value and average price, China sales quantity, value and average price, development opportunities, challenges, trends, and policies.
Chapter 2: Global Ustekinumab market share and ranking of major manufacturers, sales quantity, revenue, average price, 2020-2025
Chapter 3: China Ustekinumab market share and ranking of major manufacturers, sales quantity, revenue, average price, 2020-2025
Chapter 4: Global key producing regions of Ustekinumab, percent & CAGR, 2020-2031
Chapter 5: Ustekinumab industry chain, upstream, medium-stream, and downstream.
Chapter 6: Segment by Type, sales quantity, average price, consumption value, percent & CAGR, 2020-2031
Chapter 7: Segment by Application, sales quantity, average price, consumption value, percent & CAGR, 2020-2031
Chapter 8: Segment in regional level, sales quantity, average price, consumption value, percent & CAGR, 2020-2031
Chapter 9: Segment in country level, sales quantity, average price, consumption value, percent & CAGR, 2020-2031
Chapter 10: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, sales quantity, average price, revenue, gross margin.
Chapter 11: Conclusions